Browse Locations ... - Condition: Huntington's Disease
Intervention:
Sponsors: University of Iowa; University of Iowa; CHDI Foundation, Inc.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013 - Conditions: Extramedullary Plasmacytoma; Isolated Plasmacytoma of Bone; Light Chain Deposition Disease; Primary Systemic Amyloidosis; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: dexamethasone; Drug: cisplatin; Drug: doxorubicin; Drug: cyclophosphamide; Drug: etoposide; Drug: bortezomib; Drug: thalidomide; Drug: melphalan; Procedure: autologous stem cell transplant
Sponsors: University of Iowa; University of Iowa; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Sporadic Amyotrophic Lateral Sclerosis
Interventions: Drug: Mexiletine; Drug: Placebo
Sponsors: University of Washington; University of Washington
Not yet recruiting - verified May 2013 - Condition: Pancreatic Neoplasms
Interventions: Drug: Ascorbate; Drug: Gemcitabine; Radiation: Radiation therapy
Sponsors: University of Iowa; Joseph J. Cullen
Not yet recruiting - verified May 2013 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified May 2013 - Condition: Low Back Pain
Interventions: Procedure: Spinal treatment; Procedure: Massage
Sponsors: Palmer College of Chiropractic; Palmer College of Chiropractic
Recruiting - verified April 2013 - Conditions: Hepatic Encephalopathy; Cirrhosis
Interventions: Drug: Rifaximin; Drug: Rifaximin and Lactulose
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: fluticasone/salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Condition: Smallpox
Intervention: Biological: IMVAMUNE®
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2013 - Conditions: Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
Interventions: Drug: Ataluren; Drug: Placebo
Sponsors: PTC Therapeutics; PTC Therapeutics
Recruiting - verified April 2013 - Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013 - Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: idarubicin; Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Peripheral Arterial Disease
Interventions: Drug: edoxaban; Drug: Clopidogrel; Drug: Aspirin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; UMC Utrecht
Recruiting - verified March 2013 - Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Everolimus; Drug: Placebo (for Everolimus)
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Novartis
Recruiting - verified May 2013 - Conditions: Infant, Newborn; Infant, Moderate Preterm
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2013 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Human Insulin NPH
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (BAY 63-2521)
Sponsors: Bayer; Bayer
Available - verified April 2013 - Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine; Other: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013 - Conditions: Dense Deposit Disease; Membranoproliferative Glomerulonephritis Type II; C3 Glomerulonephritis
Intervention: Drug: CDX-1135
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013 - Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013 - Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Human Regular U-500 Insulin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Metastatic or Unresectable Cutaneous Melanoma
Interventions: Drug: MEK162; Drug: Dacarbazine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Conditions: Depressive Symptoms; Clinical Depression
Interventions: Other: Road Tour; Other: Boatload of Crosswords
Sponsors: University of Iowa; University of Iowa
Recruiting - verified April 2013 - Condition: Leishmaniasis
Interventions: Drug: MPL-SE; Drug: SE; Biological: LEISH-F3; Drug: GLA-SE
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2013 - Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Post Herpetic Neuralgia
Interventions: Drug: NXN-462; Drug: Placebo
Sponsors: NeurAxon Inc.; NeurAxon Inc.
Recruiting - verified May 2013 - Condition: CML
Intervention: Drug: AMN107
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Neoplasms
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Other: Educational DVD 1; Other: Educational DVD 2
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013 - Condition: Infertility
Interventions: Other: Morphology; Other: GemART assay
Sponsors: Gema Diagnostics; Gema Diagnostics
Recruiting - verified May 2013 - Condition: Melanoma
Interventions: Drug: Talimogene laherparepvec plus ipilimumab; Drug: Ipilimumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen; Drug: Loratadine
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Intervention: Drug: ivacaftor
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Multiple Sclerosis (MS)
Interventions: Drug: Laquinimod 0.6 mg; Drug: Matching Placebo; Drug: Laquinimod 1.2 mg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013 - Condition: Bullous Pemphigoid
Interventions: Drug: QGE031; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013 - Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013 - Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Bilogicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg); Drug: Placebo tablets
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013 - Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Everolimus
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd
Recruiting - verified May 2013 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD); Drug: VTX-2337; Drug: Placebo
Sponsors: VentiRx Pharmaceuticals Inc.; VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group
Recruiting - verified April 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Malignant Peripheral Nerve Sheath Tumors; MPNST; Sarcoma
Interventions: Drug: everolimus; Drug: bevacizumab
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; Novartis Pharmaceuticals; Genentech; Department of Defense
Recruiting - verified May 2013 - Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: FOLFOX regimen; Drug: selumetinib
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Low Back Pain
Intervention: Other: HVLA-SM
Sponsors: Palmer College of Chiropractic; Palmer College of Chiropractic; University of Iowa; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified September 2012 - Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Neurofibrosarcoma; Chondrosarcoma; Endometrial Stromal Sarcoma; Mast Cell Sarcoma; Metastatic Adult Malignant Fibrous Histiocytoma of Bone; Ovarian Carcinosarcoma; Ovarian Sarcoma; Recurrent Adult Malignant Fibrous Histiocytoma of Bone; Recurrent Adult Soft Tissue Sarcoma; Small Intestine Leiomyosarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013 - Condition: Pneumococcal Infections
Intervention: Biological: Prevnar 13 (PVC13)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2013 - Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo; Drug: HU and ruxolitinib-placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Conditions: Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: trebananib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor; Drug: Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013 - Conditions: Congestive Heart Failure; Left Ventricular (LV) Systolic Dysfunction
Intervention: Device: CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)
Sponsors: CardioKinetix, Inc; CardioKinetix, Inc
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: cUTI; Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either switch to oral therapy : 500 mg of Ciprofloxacin (oral); Drug: or switch to oral therapy : 800 mg/160 mg of sulfamethoxazole/trimethoprim
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013 - Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Aneuploidy; Down Syndrome; Noninvasive Prenatal Screening
Intervention: Device: SEQureDx Trisomy Test
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2013 - Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Conditions: Ulcerative Colitis; Left-sided Ulcerative Colitis; Distal Ulcerative Colitis
Interventions: Drug: Zoenasa-1:4; Drug: Mesalamine Enema
Sponsors: Altheus Therapeutics, Inc.; Altheus Therapeutics, Inc.
Recruiting - verified May 2013 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant dimeglumine; Drug: Fosaprepitant Placebo; Drug: Dexamethasone; Drug: Ondansetron; Drug: Dexamethasone Placebo; Drug: Ondansetron Placebo; Drug: Rescue Therapy
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Severe Aortic Stenosis
Interventions: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Procedure: Surgical Aortic Valve Replacement (SAVR)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013 - Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified May 2013 - Conditions: Primary Immunodeficiency; Agammaglobulinemia; Hypogammaglobulinemia; Antibody Deficiency
Intervention: Biological: Kedrion IVIG 10%
Sponsors: Kedrion S.p.A.; Kedrion S.p.A.
Recruiting - verified May 2013 - Condition: Driveline Heart-assisted Device Related Infection
Intervention:
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013 - Condition: Urinary Bladder, Neurogenic
Interventions: Drug: Fesoterodine 4 mg; Drug: Fesoterodine 8 mg; Drug: Oxybutynin; Drug: Fesoterodine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Conditions: Down Syndrome; Fetal Aneuploidy
Intervention:
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium + olodaterol (high dose); Drug: tiotropium+olodaterol; Drug: placebo to tiotropium+olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Conditions: Metastatic Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
Interventions: Drug: INNO-206; Drug: Doxorubicin
Sponsors: CytRx; CytRx
Recruiting - verified May 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Conditions: Chronic Myocardial Ischemia; Refractory Angina Pectoris; (Advanced) Coronary Heart Disease
Interventions: Biological: Auto-CD34+ cells; Biological: Placebo: Diluent used to suspend Auto-CD34+ cells; Other: Standard of care
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2013 - Conditions: Liposarcoma; Surgically Unresectable Liposarcoma; Metastatic Liposarcoma
Intervention: Drug: pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013 - Conditions: Metastatic Colorectal Cancer; Colorectal Cancer
Interventions: Drug: MORAb-004; Drug: Placebo
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2013 - Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2013 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified April 2013 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013 - Conditions: Heart Failure; Cardiac Failure; Acute Decompensated Heart Failure (ADHF)
Interventions: Device: Isolated veno-venous ultrafiltration (AQ); Drug: IV Loop Diuretics (LD)
Sponsors: Gambro Renal Products, Inc.; Gambro Renal Products, Inc.; Gambro UF Solutions, Inc.
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo; Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream; Drug: Dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013 - Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified May 2013 - Conditions: Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: veliparib; Drug: carboplatin; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013 - Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Influenza
Interventions: Biological: Sanofi Pasteur Fluzone® High Dose; Biological: Sanofi Pasteur Fluzone®
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: Alliance for Clinical Oncology Trials; North Central Cancer Treatment Group; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified January 2013 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013 - Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Recurrent Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: Akt inhibitor MK2206; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2013 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013 - Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Bronchopulmonary Dysplasia
Interventions: Drug: Hydrocortisone; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified May 2013 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; German Low Grade Lymphoma Study Group; Institute of Cancer Research, United Kingdom
Recruiting - verified May 2013 - Conditions: Chondrosarcoma; Metastatic Chondrosarcoma
Intervention: Drug: pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013 - Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified April 2013 - Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013 - Condition: Influenza, Human
Interventions: Drug: Oseltamivir; Drug: Oseltamivir Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013 - Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013 - Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: ofatumumab; Drug: bendamustine hydrochloride; Drug: bortezomib; Other: laboratory biomarker analysis; Procedure: positron emission tomography with radiolabeled targeting agents; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Crohn's Disease
Intervention: Drug: PF-00547659
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Cancer; Stage IVB Cervical Cancer
Interventions: Drug: veliparib; Other: immunohistochemistry staining method; Other: diagnostic laboratory biomarker analysis; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerConditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Biological: cetuximab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2013 - Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013 - Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Human Papillomavirus Infection; Cervical Neoplasia
Interventions: Procedure: Gynaecological follow-up; Biological: Cervarix™; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2013 - Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib; Drug: temozolomide; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Herpes Zoster
Interventions: Drug: Placebo; Biological: ZOSTAVAX® (Zoster Vaccine Live)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Conditions: Interstitial Cystitis; Chronic Prostatitis
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
Recruiting - verified May 2013 - Conditions: Fibromyalgia; Irritable Bowel Syndrome; Fatigue Syndrome, Chronic
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
Recruiting - verified May 2013 - Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2013 - Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: Observation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified May 2013 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: Coreg CR®; Drug: lisinopril; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified May 2013 - Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Multiple Myeloma; Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min); Drug: Group B=CrCL<30 mL/min not on dialysis; Drug: Group C=CrCL<30 mL/min and on dialysis
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Celgene Corporation
Recruiting - verified May 2013 - Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013 - Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); BSN Medical Inc; Genentech; Covidien; BayerHealthcare; Mid America Heart Institute; Society of Interventional Radiology Foundation; Massachusetts General Hospital
Recruiting - verified May 2013 - Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease
Intervention: Behavioral: Supplemental oxygen therapy
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Centers for Medicare and Medicaid Services
Recruiting - verified May 2013 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified April 2013 - Condition: Depression, Postpartum
Interventions: Drug: Sertraline; Drug: Placebo; Behavioral: Interpersonal psychotherapy (IPT); Behavioral: Clinical management; Behavioral: Mothercrafting
Sponsors: Women and Infants Hospital of Rhode Island; Women and Infants Hospital of Rhode Island; National Institute of Mental Health (NIMH)
Recruiting - verified May 2013 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Condition: Kidney Transplant
Interventions: Drug: ramipril; Drug: ramipril
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013 - Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Advanced Gastric Cancer; Advanced/Metastatic Non-small Cell Lung Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastatic Castration-resistant Prostate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013 - Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013 - Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013
 |
Find Paid Research Studies in Ackley, Iowa |
Clinical Trial Locations 